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including early metabolic dysfunctions, enhanced oxidative 
stress and distorted energy homeostasis. The epigenetic 
changes of clock genes driving metabolic disease and obe-
sity development have also been included in this review. Fi-
nally, we have also underlined the relevance of metabolic 
homeostasis regulation by central and peripheral organ 
clocks, sleep disturbances, nutrients, and feeding time, as 
key factors in obesity development as well as both, classical 
and chronotherapeutic approaches for its prevention and 
treatment.  © 2016 S. Karger AG, Basel 
 Introduction 
 Although obesity is a preventable disease, its preva-
lence is continuously increasing worldwide  [1] ; and be-
cause it is frequently associated with other cardiovascular 
risk factors and high mortality, obesity has become an 
important public health problem and a heavy socioeco-
nomic burden for the overall society  [1, 2] .
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 Abstract 
 A combined neuroendocrine, metabolic, and chronobiolog-
ical view can help to better understand the multiple and 
complex mechanisms involved in obesity development and 
maintenance, as well as to provide new effective approaches 
for its control and treatment. Indeed, we have currently up-
dated data on the whole adipogenic process involved in 
white adipose tissue (WAT) mass expansion, namely due to 
a mechanism whereby WAT cells become hypertrophic, thus 
inducing a serious local (WAT) inflammatory condition that 
in turn, will impair not only the cross-talk between the hypo-
thalamus and the WAT, but also favoring the development 
of deep and widespread neuroendocrine-metabolic dys-
function. Moreover, we also have revisited the circadian 
clock genes involved in dysfunctional WAT mass expansion 
and the mechanisms that may lead to obesity development, 
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 Overweight and obesity are defined as abnormal or ex-
cessive fat accumulation and though not generally accept-
ed, its diagnosis is still based on an anthropometric con-
cept (body mass index; BMI). In fact, many incongruities 
weaken the value of BMI as a cornerstone of the current 
obesity classification system, but the reliance upon this 
simple tool still goes on  [3] .
 The excessive fat accumulation, either in white adipose 
tissue (WAT) or other organs, is the consequence of hy-
pertrophy and hyperplasia of white adipocytes in a con-
text of positive energy balance  [4] . This balance is con-
trolled mainly at the hypothalamic level by a complex cir-
cuitry of orexigenic and anorexigenic signals  [5] and by 
an endogenous clock that sets a circadian rhythm of ap-
petite-satiety, a function highly affected by modern life 
habits  [6] .
 WAT is currently recognized as an active endocrine 
organ that synthesizes and releases multiple adipokines 
that also plays several paracrine and autocrine roles  [7] . 
These adipokines, together with those produced by infil-
trating macrophages (cytokines), also exert proinflam-
matory activity in pathological conditions  [7] . Conse-
quently, obesity is the result of a multifactorial combi-
nation of genetic background, metabolic, endocrine, 
inflammatory and circadian dysfunctions, whose long-
term maintenance is favored by behavioral disorders  [1] .
 Considering the key role of energy homeostasis for the 
normal development and maintenance of body functions, 
its control must be ensured by a complex self-tuned ser-
vo-mechanism established between body organs with 
participation of many hormones as main signals as sche-
matically shown in  Figure 1 . Indeed, food intake triggers 
the release of several gut hormones (glucagon like pep-
tide-1 [GLP-1], glucose-dependent insulinotropic poly-
peptide, cholecystokinin, oxyntomodulin) that inhibit/
slow gastric emptying/acid release, strongly modulate en-
docrine pancreas function (enhance insulin and decrease 
glucagon secretion) and inhibit brain neuropeptide Y, 
peptide YY and GLP-1. Moreover, high serum insulin 
levels will additionally impact on the hypothalamus (sa-
tiety effect) and WAT (enhanced leptin [LEP] release), 
thus summing their activities to the above-mentioned 
ones to reinforce appetite inhibition. This complex mod-
ulator interaction also affects glycemia homeostasis. Al-
teration in these fine-tuned mechanisms causes serious 
metabolic diseases, such as obesity and type 2 diabetes. 
Analyzing how some of these peripheral signals interact 
with hypothalamic neurons (mainly located at the arcuate 
nucleus [ARC]) involved in the control of the brain ap-
petite/satiety circuitry, indicates that WAT-derived LEP 
stimulates the melanocortinergic system and neurons 
producing strong anorexigenic peptides (proopiomela-
nocortin and cocaine- and amphetamine-regulated tran-
script) peptide. Interestingly, insulin shares a similar ano-
rectic effect by acting directly (through its binding to in-
sulin receptor) upon the same neurons. Both signals act 
in ARC neurons through their binding to their active re-
ceptors (the long isoform of LEP receptor [ObRb] and 
insulin receptor, respectively). As mentioned above, gut-
released peptide YY and GLP-1 impact upon ARC neu-
rons together with insulin and LEP, inhibiting orexigenic 
activities, such as neuropeptide Y- and agouti-related 
protein-producing neurons.
 We may also assume that this complex mechanism 
could be easily altered by environmental factors mainly 
when they act repeatedly and over a long period of time. 
In this context, the aim of this review is to briefly analyze 
the role of 2 of them in the development of obesity: WAT 
development and its dysfunction associated with impair-
ment of its circadian control. Within this scope, we there-
after propose a potential chronobiological therapeutic 
approach for its effective prevention, control, and treat-
ment.
 Looking for a Dysfunctional Starting Point 
 Because obesity is tightly related to WAT mass, it is 
reasonable to identify its origin and function when trying 
to understand its pathophysiological basis. Accordingly, 
we will start briefly describing the adipogenic process, its 
regulation and dysfunction.
 Expansion and renewal of the adipocyte pool in WAT 
depends on the adipogenic process. This process includes: 
(a) the commitment of mesenchymal stem cells (MSCs) 
 [8] into adipocyte precursor cells (APCs) located within 
the adipose stromal cell (ASCs) population  [9] , thus ac-
quiring adipogenic potential and restricting them to adi-
pocyte fate, and (b) a final differentiation of APCs to ma-
ture adipocytes ( Fig. 2 ). APCs are similar to bone marrow 
MSCs  [10–12] and support vascularization as mural/ad-
ventitial cells secreting angiogenic factors  [13, 14] . APCs 
have been identified within the adipose stromal cell pop-
ulation based on the expression of mesenchymal mark-
ers, such as platelet-derived growth factor receptor-β 
(PDGFRβ, aka CD140b) and pericyte markers  [15–18] .
 APC differentiation is highly modulated by endocrine 
and metabolic factors such as insulin and glucocorticoid 
(GC) working either individually or in combination  [19] . 
On the other hand, WAT mass expansion could result 
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from either cell tissue hyperplasia (increased number of 
normal mature “small-size” adipocytes) or their hyper-
trophy (increase in the size of dysfunctional adipocytes). 
Normal adipogenesis (newly generated “small-size” adi-
pocytes), occurs when WAT mass needs to be recovered, 
for example during/after a long-term period of negative 
energy balance. In these circumstances, the new adipo-
cytes develop a normal function. On the other hand, in 
rats with chronic high serum levels of LEP, GC and insu-
lin, their visceral WAT undergoes a marked reduction in 
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 Fig. 1. Interrelationship between signals from the hypothalamus 
and peripheral tissues involved in maintaining energy homeosta-
sis. A schematic model showing the complex net of neuroendo-
crine and metabolic signals that the system employs to assure tight 
control of energy homeostasis. To attain such control, peripheral 
tissues release different products that settle a feedback system 
among them as well as with the hypothalamus. ARC, hypothalam-
ic arcuate nucleus; NPY, neuropeptide Y; CART, cocaine- and am-
phetamine-regulated transcript; ObRb, long isoform of leptin re-
ceptor; LEP, leptin; IR, insulin receptor; INS, insulin; MCs, mela-
nocortin system; PYY, peptide YY; GLP-1, glucagon like peptide-1; 
GRE, glucose regulatory elements; WAT, white adipose tissue; 
RES, resistin; ADIPOQ, adiponectin; GIP, glucose-dependent in-
sulinotropic polypeptide; CCK, cholecystokinin; OXM, oxynto-
modulin (for detailed description see Introduction). Solid and
dotted arrows indicate stimulation and inhibition, respectively. 
Adapted from Gagliardino  [153] . 
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the number of compromised APCs, namely white APCs 
(WAPs), and a significant delay in their capacity to dif-
ferentiate into mature adipocytes  [20] ; consequently, the 
local WAT pad becomes full of dysfunctional-hypertro-
phic adipocytes  [21] , a situation reverted by normaliza-
tion of the high endogenous GC milieu  [21] .
 When WAT mass increases by adipocyte hypertrophy, 
these large-size adipocytes develop a secretory dysfunc-
tion characterized by overproduction (synthesis and re-
lease) of adipokines that decrease tissue sensitivity to in-
sulin, promote oxidative stress (OS), and display proin-
flammatory effects (LEP, resistin, tumor necrosis factor-α, 
plasminogen activator inhibitor type 1, interleukin-1 [IL-
1], IL-6); conversely, they release lower amounts of adipo-
nectin (ADIPOQ; an insulin-sensitizing adipokine)  [22] .
 OS (either local or as part of a general one) also im-
pacts on large-size adipocyte function such as their own 
insulin sensitivity, thus establishing a vicious circle that 
perpetuates their dysfunction  [23] . The multifactorial ad-
ipocyte dysfunction and the participation of macrophages 
(WAT infiltration) in the whole process result in other 
tissues’ dysfunction that affects the overall homeostasis as 
summarized in  Figure 3 . Within this scenario, 3 main 
dysfunctions play a key pathogenic role: (1) enhanced re-
lease of LEP that impairs tissue sensitivity to insulin (in-
sulin resistance [IR])  [24] , (2) the prolonged high serum 
LEP levels that induce down-regulation of LEP receptors 
(ObRb) at pancreatic β- and α-cell level (as in other tis-
sues as well), thus impairing its negative feedback mecha-
nism on both insulin and glucagon secretions  [25, 26] , 
and (3) increased release of proinflammatory adipokines 
(mainly tumor necrosis factor-α, IL-1, and IL-6) that act-
ing on the medial basal hypothalamus, activate the hypo-
thalamo-pituitary-adrenal axis with the consequent in-
creased release of GCs  [27, 28] . This multifactorial meta-
bolic and endocrine dysfunctions lead to overall insulin 
and LEP resistance ( Fig. 4 ) as well as to a pro-oxidative 
and proinflammatory states ( Fig. 3 ) that reinforce WAT 
and hypothalamic dysfunctions, setting a serious impair-
ment in the energy homeostasis  [29, 30] .
 Regarding the modulatory effect of metabolism and 
dietary composition on APC differentiation, it has been 
shown that 8-week fructose-rich diet (FRD) administra-
tion induces several alterations, such as high plasma levels 
of insulin, LEP and triglyceride associated with increased 
mass of retroperitoneal adipose tissue (RPAT). Indeed, 
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 Fig. 2. Adipogenesis. The adipogenic process involves 2 sequential 
steps: commitment of mesenchymal stem cells (MSCs) into adi-
pose tissue precursor cells (APCs), acquiring the adipogenic po-
tential and restricting them to the adipocyte linage, followed by 
terminal adipocyte differentiation. In the first step, APCs begin to 
express CD34, a cell surface antigen that distinguishes between 
adipogenic and nonadipogenic cell subpopulations. The CD34+ 
cell subpopulation expresses almost exclusively the transcriptional 
factor Zfp423, which in turn activates the basal expression of 
PPAR-2, a key proadipogenic signal that assures APC conversion 
into adipocytes. The differential expression of both transcription-
al factors determines the cell’s ability to differentiate into adipo-
cytes upon the action of adipogenic stimulus (competency). There-
after, and in response to the adipogenic stimuli (mainly endoge-
nous glucocorticoid and insulin), APCs differentiate into mature 
adipocytes, cells characterized by intracellular lipid storage, adi-
pokine production and insulin responsiveness. CD34, cell surface 
antigen distinguishing adipogenic from nonadipogenic cells; 
PPARγ-2, peroxisome proliferator receptor-γ-2; Zfp423, zinc fin-
ger protein 423; Pref-1, preadipocyte factor-1; Wnt10b, wingless 
type MMTV integration site family member 10b; MR, mineralo-
corticoid receptor; GR, glucocorticoid receptor. 
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the RPAT pad has 2 adipocyte populations: one similar to 
and another larger than the ones identified in the normal 
(control) group, thus suggesting that this AT pad mass 
expansion could result from a combination of newly gen-
erated adipocytes (adipogenesis) and hypertrophy of the 
existing ones  [22, 31–33] .
 As mentioned before, the adipogenic process involves 
2 sequential steps: commitment of MSCs into APCs, ac-
quiring adipogenic potential and restricting them to the 
adipocyte linage, followed by terminal adipocyte differ-
entiation  [34] . In the first step, APCs begin to express 
CD34, a cell surface antigen that distinguishes between 
adipogenic and nonadipogenic cell subpopulations  [35] . 
This CD34+ cell subpopulation expresses almost exclu-
sively the transcription factor zinc finger protein 423 
(Zfp423)  [36] , which in turn activates the basal expres-
sion of PPARγ-2, a key proadipogenic signal that assures 
APC conversion into adipocytes  [37] . The differential ex-
pression of both transcription factors determines the 
competency of APCs, i.e. a cell’s capacity to differentiate 
into adipocytes upon the appropriate action of adipogen-
ic stimuli  [34] ; these newly generated cells are character-
ized by intracellular lipid storage, adipokine production, 
and insulin responsiveness.
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 Fig. 3. White adipose tissue (WAT) and inflammation: neuroen-
docrine-metabolic consequences. A combination of genetic back-
ground, unhealthy diet, and sedentary lifestyle can induce hyper-
trophic increase in WAT mass associated with macrophage infil-
tration, leading to an abnormal pattern of adipokine production/
release. Enhanced WAT-derived leptin release, in turn, impairs 
tissue sensitivity to insulin (insulin resistance, IR). Thereafter, the 
prolonged hyperleptinemia could induce ObRb downregulation, 
namely at the pancreatic (β- and α-cell) level, thus impairing its 
negative feedback mechanism on both insulin and glucagon secre-
tions; moreover, the increased release of proinflammatory signals 
(TNF, IL-1, IL-6, and C-reactive protein [CRP], among others) will 
worsen several functions. In fact, overall WAT dysfunction pro-
motes multiple endocrine-metabolic dysfunctions, such as insulin 
resistance (IR), enhanced reticulum endoplasmic oxidative stress 
(REOS), enhanced lipolytic activity, cell hypoxia, and apoptosis. 
These alterations affect multiple organs, namely HPA axis, liver, 
muscle, endocrine pancreas, and endothelium functions. FFA, free 
fatty acid; JUNK, Janus kinase; NF-κB, nuclear factor-κB; HGP, 
hepatic glucose production; NAFLD, nonalcoholic fatty liver dis-
ease; NASH, nonalcoholic steatohepatitis; DMT2, diabetes melli-
tus type 2. Adapted from Cusi  [154] . 
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 In fact, the above-mentioned administration of an 
FRD for 8-weeks induces an increase in mRNA expres-
sion levels of PPARγ-2 and Zfp423, indicating that high 
APC competency is maintained during this period. This 
phenomenon might be responsible for the small new ad-
ipocyte population observed in these rats, as discussed 
before. Because FRD intake did not modify APC expres-
sion of 2 antiadipogenic factors Pref-1 and Wnt10b, its 
effect could be mainly ascribed to changes in APC com-
petency.
 Altogether, these results demonstrate that long-term 
FRD intake altered the RPAT APC by enhancing their 
adipogenic potential. The fact that this fructose-induced 
enhancing effect can be reproduced in vitro and is blunt-
ed by its replacement by glucose in the culture medium 
strongly suggests that fructose directly and specifically 
modulates the adipogenic competency  [33] . This effect 
was also demonstrated in rats born from mothers fed with 
an FRD during pregnancy. At 60 days of age, these rats 
portray impaired glucose tolerance and high circulating 
levels of LEP, while their RPAT mass shows an enhanced 
LEP gene expression and the presence of hypertrophic 
adipocytes that oversecrete LEP  in vitro  [38] .
 Chronic circadian desynchronization induced by re-
peated changes in the 12-h light-dark cycle twice a week, 
increases food intake, body weight, and RPAT mass in 
male F344 rats. Proteomic studies demonstrated that this 
circadian alteration induces an upregulation of 2-DE pro-
tein spots of proteins involved in carbohydrate metabo-
lism and in the citric acid cycle, thus suggesting a positive 
energy balance status  [39] . The simultaneous upregula-
tion of hypothalamic γ-amino butyric acid (GABA) ami-
notransferase present in these animals, suggests a link be-
tween the brain GABA-ergic system and the food intake 
modulation; furthermore, the upregulation of different 
metabolic parameters (fatty acid-binding protein 4) and 
downregulation of 78-kDa glucose-regulated protein in 
WAT, implies the development of IR. These findings par-
tially reproduced the changes induced by genotype and a 
high-fat diet, reinforcing the concept that circadian 
rhythm alteration plays an important role in obesity de-
velopment and associated homeostatic dysfunction.
 Potential Effect of Intervention upon WAP Cells on 
Obesity Development  
 Daquinag et al.  [40] have shown that targeted WAP 
cytoablation results in a long-term WAT growth suppres-
sion, despite increased caloric intake in a mouse model
of dietary-induced obesity. They also showed that WAP 
depletion results in a compensatory population of beige 
adipocytes. Consistent with the reported thermogenic
capacity of the later tissue, WAP-depleted mice display 
increased energy expenditure. Thus, targeting white
adipocyte progenitors could render an effective strategy 
to sustained modulation of WAT metabolic activity  [40] .
 Circadian Modulation of Energy Metabolism 
 The Circadian Clock: Its Molecular Mechanism,
Its Components, and Its Role in the Development of 
Metabolic Dysfunctions 
 There is clear evidence that energy metabolism is 
modulated by the circadian clock at both central and local 
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 Fig. 4. Dysfunction of main endogenous adipogenic signals. En-
hanced white adipose tissue (WAT) mass, at the expenses of adi-
pocyte hypertrophy, results in hyperleptinemia that, if established 
for a long time, could result in a leptin-resistant state. As a result 
of the lack of the leptin-inhibiting effect, 2 system functions be-
came mainly hyperactive: the pancreatic β-cells and the corticoad-
renal cells. Such hyperactivity increases the circulating levels of 
both insulin and GC, which in due time will perpetuate and aggra-
vate the adipogenic process; these changes lead to a hypertrophic 
expansion of WAT mass characterized by exacerbated proinflam-
matory adipokine production and enhanced oxidative stress. INS, 
insulin; LEP, leptin; GC, glucocorticoid; AC, adrenal cortex; 
ACTH, adrenocorticotropic hormone; AP, anterior pituitary. The 
question mark is included because the ACTH inhibitory effect on 
WAT LEP production has been addressed in 3T3-L1 adipocytes 
only; see Norman et al.  [155] . 
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levels. The central pacemaker or circadian clock prepares 
individuals for predictable events such as turning from 
day to night, and thereby synchronizing physiological 
functions to particular daytime periods in order to opti-
mize metabolic efficiency. Other factors contribute to the 
synchronizing process such as light-dark cycle, food in-
take, exercise, and sleep. On account of the existence of 
their synchronized activity, we can envisage the potential 
use of a “chronotherapeutic approach for obesity,” which 
we will discuss later in this review.
 The central pacemaker is located at the hypothalamic 
suprachiasmatic nucleus (SCN), though the mammalian 
circadian system also comprises peripheral oscillators lo-
cated in almost every cell of the body  [41, 42] . This mul-
tiple individual tissue-specific cellular clock system is 
based on a small number of core clock genes interlocked 
by transcriptional and posttranslational feedback loops 
 [41] . The positive drive for the daily clock is constituted 
by 2 transcription factors encoded by Bmal1 and Clock 
genes. They form heterodimeric complexes that control 
the transcription of other clock genes named Period 
(Per1/Per2/Per3) and Cryptochrome (Cry1/Cry2), which 
in turn provide the negative feedback signal that shuts 
down the positive drive ( Fig. 5 ). Any alteration in this ac-
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 Fig. 5. A master regulatory role of the circadian clock in the meta-
bolic pathways. Circadian clock proteins (CLOCK, BMAL, PERs, 
CRYs, REV-ERBs) regulate metabolism by interacting with cell 
energy and redox balance through different mechanisms such as 
sensing specific metabolites (e.g., NAD, NADP, ATP) and inter-
acting with specific genes in a wide range of metabolic areas: lipid 
and carbohydrate homeostasis. These mechanisms are both direct 
and chromatin-mediated, with important interventions of pro-
teins like SIRT (belonging to the deacetylase family). 
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curate mechanism initiates misalignment with multiple 
metabolic effects.
 To support this concept, we will analyze evidence on 
how metabolism, particularly glucose homeostasis and 
adipogenesis, is affected when clock members are mu-
tated or even absent due to knockout (KO) technology. 
The concept that disruption of circadian rhythms en-
hances the risk of metabolic diseases such as obesity, type 
2 diabetes mellitus (T2DM), and the metabolic syndrome 
arises from the observation of clock member KO genes in 
mice. Administration of a hypercaloric diet to Clock mu-
tant mice resulted in accumulation of energy and body 
mass to values double than those recorded in control an-
imals  [43] . These mice also have hyperglycemia, hypoin-
sulinemia  [42] , hyperphagia, obesity, impaired gluconeo-
genesis, and lipid homeostasis  [43, 44] . Mice with Per3 
KO alter their body mass and composition and accumu-
late fat by enhancing adipogenesis  [45, 46] . Moreover, 
Bmal1 KO mice have impaired glucose and lipid homeo-
stasis  [47] as well as lack of rhythmicity in insulin action 
and activity patterns that can be restored by the paralo-
gous gene Bmal2. Interestingly, Per3 KO also show im-
paired lipid metabolism and obesity when fed a high-fat 
diet  [48] . Conversely, constant expression of Per3 inhib-
ited adipogenesis in MSCs  [45] . Otherwise, Per2 blocks 
recruitment of PPARγ to target promoters in genes in-
volved in the control of adipogenesis and insulin sensi-
tivity, while its absence results in enhanced adipocyte
differentiation  [49] . Furthermore, overall body glucose 
regulation during the day is organized by the liver pe-
ripheral molecular clock  [48, 49] . Altogether, this evi-
dence demonstrates that circadian disruption leads to IR 
and obesity, thus lending additional support to the crucial 
roles played by circadian clock genes in both adipogenesis 
as well as glucose and lipid homeostasis, particularly in 
adipose tissue  [50] . The fact that half of the nuclear recep-
tors identified in the liver and adipocytes exhibit a 24-h 
periodicity lends further support to this assumption  [51, 
52] .
 Circadian regulatory mechanisms utilize both neural 
and humoral communication to tightly control insulin, 
LEP, and glucose peripheral levels  [53] , and rats with 
hampered CNS function showed abnormalities in glu-
cose metabolism and insulin effect  [54–56] . Similarly, 
Clock mutant mice showed impaired glucose utilization 
and appetite control  [42, 43, 47] . At the clinical level, sev-
eral studies have also shown that CLOCK variants corre-
late with BMI  [57] , weight loss, sleep duration and total 
plasma cholesterol concentration in obese Caucasian 
people  [58] . CLOCK and CRY1 polymorphisms might be 
involved in individual susceptibility to abdominal obesity 
in the Chinese Han population  [59] . Variants of the cir-
cadian clock-related gene Mntr1b, which encodes pineal 
hormone melatonin receptor 1B, portrait impaired glu-
cose-induced insulin secretion, abnormal fasting glyce-
mia and a higher risk of developing T2DM  [60–65] thus 
conditioning, at least in part, melatonin actions. Addi-
tionally, melatonin synthesis and release undergo strong 
daily oscillations regulated by the master circadian clock 
in the CNS and by light.
 Single nucleotide polymorphisms (SNPs) in the brain-
muscle-ARNT-like protein-2 (BMAL2) gene have also 
been associated with high risk of developing T2DM in 
obese patients  [66] . Cross-sectional studies have reported 
associations between the CLOCK locus and prevalence of 
obesity, plasma glucose levels, hypertension, and T2DM. 
Recently, further associations with cardiovascular disease 
(CVD) have been found (association between a CLOCK 
polymorphism and stroke in T2DM), suggesting that 
core clock genes may significantly contribute to increased 
CVD risk in T2DM  [67] . All these genome-wide associa-
tion studies in human population support experimental 
evidence for a genetic link between the circadian clock, 
overall metabolism, and susceptibility to metabolic dis-
ease, particularly obesity.
 Circadian Clock Dysfunction and Obesity 
 Apparently, synchronization of many different meta-
bolic pathways, through gene expression and their down-
stream activation with feeding time, may represent an 
adaptive evolution to improve and optimize energy bal-
ance. Thus, we will briefly review reported evidence of 
glucose homeostasis regulation by circadian clocks and 
how disruption of circadian rhythms drives to pathologi-
cal states such as obesity, metabolic syndrome, and T2DM 
 [55, 56] .
 The correlation between increased occurrence of obe-
sity and the ubiquity of modern social habits, such as light 
at night (LAN), unusual meal timing, irregular sleep/
wake schedules and traveling between different time 
zones, all encompassed by a 24 h/7 days lifestyle, strongly 
suggests that impairment of the circadian system is in-
volved in the etiology of several illnesses. It has been re-
ported that even slight changes in LAN alter meal timing 
and body mass accumulation in mice  [68, 69] . Several 
clinical surveys have also shown increased prevalence of 
obesity in night-shift workers, showing that artificial 
lighting may contribute to increased prevalence of meta-
bolic disorders  [70, 71] . Altogether, this evidence suggests 
that inappropriate time administration of food may dis-
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rupt the normal metabolic profile, leading to a desyn-
chronized state causally linked to obesity development. In 
this regard, medical students portraying nocturnal life 
habits showed decreased plasma melatonin and LEP 
peaks. However, plasma glucose concentration remained 
high during the night while insulin secretion decreased 
markedly, thus indicating that nocturnal life impairs in-
sulin response to glucose, likely becoming one of the risk 
factors associated with modern social habits  [72] . Circa-
dian misalignment also alters circulating LEP levels, an 
effect that may negatively affect appetite and energy bal-
ance  [73–75] . The increased obesity rate recorded in 
100,000 women of the Breakthrough Generations Study, 
associated with increased levels of LAN exposure, sup-
ports this assumption  [70] . Moreover, data from nurses 
and midwives showed that they had a higher risk of de-
veloping obesity  [71] . Thus, both animal models and hu-
man data have clearly proved that circadian disruption 
leads to IR and obesity  [50] .
 On the other hand, genetic modifications causing obe-
sity and diabetes lead to circadian disruption. Genetically 
obese and diabetic db/db mice, lacking Ob-Rb, are ar-
rhythmic regarding feeding and general activity; they 
present an extended endogenous period and altered pho-
tic integration  [76] . The same group has demonstrated 
that LEP modulates daily blood glucose rhythmicity by 
modulating food intake  [77, 78] . Additionally, rats sub-
mitted to forced activity during the sleeping phase, showed 
altered temporal pattern of food intake, loss of glucose 
rhythmicity and a reversed rhythm of triacylglycerol lev-
els, though CNS activity was intact. Similarly, in night 
workers the combination of altered work and eating ac-
tivities, may lead to internal desynchronization by uncou-
pling metabolic functions from the biological clock which 
remained fixed to the LD cycle  [74, 75, 79, 80] . Further-
more, feeding mice at the wrong time (inactive or sleeping 
phase), desynchronizes peripheral clocks and causes obe-
sity by inducing hyperphagia, physical inactivity, LEP re-
sistance, hepatic lipid accumulation, and hyperadiposity. 
Liver and skeletal muscle metabolic rhythms become un-
coupled as shown by temporal expression of desynchro-
nized circadian clock genes in the skeletal muscle  [81] .
 It has also been shown that an abnormal metabolic re-
sponse such as obesity, to a given nutritional challenge, 
depends on the combination of several genes’ action rath-
er than on a single one, and even to a precise localization 
at a tissue level of such combination. Bmal1 KO mice 
show different metabolic impairment depending on the 
tissue affected. Deletion of this allele in adipose tissue 
(ABKO), as well as its combined deletion in liver and ad-
ipose tissue (LABKO), alters feeding behavior and loco-
motive activity. However, animals with the combination 
of liver and adipose deletion only develop obesity after 
exposure to a diabetogenic diet  [82] . Deletion of Bmal1 in 
adult murine β-cells resulted in impaired metabolic adap-
tation to high fat diet: they display fasting and diurnal 
hyperglycemia, impaired glucose tolerance, loss of glu-
cose-stimulated insulin secretion and lack of β-cell ex-
pansion. This observation points to β-cell circadian clock 
as a novel regulator of compensatory β-cell expansion in 
response to an increased insulin demand, induced by ad-
ministration of an obesogenic diet. Because obesity and 
IR are risk factors for developing T2DM and even when 
not every individual exposed to a cafeteria diet will be-
come diabetic, it is important to identify key factors in-
volved in a proper response to defiant lifestyles  [83] .
 At the clinical level, in a recent survey, samples of sub-
cutaneous adipose tissue from 50 overweight subjects 
were collected before and after 8 weeks of administration 
of a hypocaloric diet (800 kcal/day plus 200 g vegetables/
day). The expression of core clock genes (assayed by 
quantitative real time PCR), Per2 and NR1D1, was in-
creased after the weight loss, and their levels correlated 
with this decrease and the expression of several genes in-
volved in fat metabolism (FASN, LPL, PPARG, PGC1A, 
ADIPOQ), energy metabolism (SIRT1), and inflamma-
tion. Thus, clock gene expression in human subcutaneous 
adipose tissue is regulated by body weight changes and 
associated with BMI, serum cholesterol levels and the ex-
pression of metabolic and inflammatory pathways in-
volved in adapting adipose tissue metabolism to changes 
in energy intake  [84] .
 Because the circadian pattern of adipokines is blunted 
in obese subjects, another study tested the possibility that 
bariatric surgery could restore it. Surgical intervention 
rapidly decreased 24-h LEP levels but, after 3 months, it 
did not recover the physiological nocturnal rise of LEP 
levels present in lean subjects  [85] . On the other hand, 
stimulated lipolysis by activated natriuretic peptide re-
ceptors undergoes circadian regulation  [86] , as well as 
adiponectin expression through the circadian expression 
of its transcription factor PPARγ and its coactivator 
PGC1α  [87] .
 Circadian Regulation of Epigenetic Changes in Obesity 
and Other Metabolic Diseases 
 A link between epigenetic changes (DNA acetylation/
methylation) of the circadian clock system and metabo-
lism has already been described. In this regard, it has been 
shown that the molecular clock regulates the rhythm
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of NAD (nicotinamide adenine dinucleotide 1), an im-
portant cofactor of the histone deacetylase sirtuin (si-
lent mating type information regulation 2 homolog) 1 
(SIRT1). In this way, the clock controls SIRT1 effects on 
other genes: through protein acetylation/deacetylation 
and chromatin modification, it regulates oscillating ex-
pression of metabolic genes. Particularly in hepatocytes, 
the Rev-erba rhythm orchestrates the binding of histone 
deacetylase 3 (HDAC3), causing chromatin modification 
that coordinates the expression of lipid metabolic pattern. 
Rhythmicity disruption of DNA binding and HDAC3 
deacetylation leads to liver steatosis  [88–93] . Further as-
sociation between the methylation status of clock genes 
(CLOCK, Bmal1, and Per2) with obesity, metabolic syn-
drome, and weight loss has been also reported. Interest-
ingly, this methylation status could be used as a biomark-
er to predict weight loss success  [94] .
 A recent study has demonstrated that a weight loss in-
tervention based on an energy-controlled Mediterranean 
diet, may influence the methylation levels of 3 clock genes, 
Bmal1, CLOCK, and NR1D1, being an association be-
tween the methylation levels and the diet-induced serum 
lipid profile (total cholesterol and low-density lipopro-
tein cholesterol). Further, significant and positive corre-
lations were found between changes in the methylation 
levels in the CpG 5–9 region of Bmal1 due to the interven-
tion and changes in serum lipids  [95] .
 Circadian Regulation of OS, Energy State, and 
Metabolic Functions 
 We have already mentioned that the extra adipose tis-
sue found in the obesity condition provides excess of ad-
ipokines that increase both inflammation and oxidative 
damage of proteins and lipids. We have to stress that most 
enzymes responsible for the antioxidant defense are un-
der circadian control, and when their expression pattern 
is impaired by a high-fat diet (HFD), this effect may be 
prevented by melatonin administration  [96] . This con-
trol includes the regulatory role of redox coenzymes 
(NAD(P)+/NAD(P)H, GSH/GSSG), reactive oxygen spe-
cies (superoxide anion, hydrogen peroxide), and antioxi-
dants (melatonin)  [97] .
 Sleep and Obesity 
 Traditional lifestyle factors such as unbalanced diet 
and physical inactivity are not the only players involved 
in the dramatic rise in the incidence and prevalence of 
T2DM. In this regard, Arora and Taheri  [98] have re-
viewed the evidence supporting sleep as a new important 
lifestyle abnormal behavior.
 In a recent study, performed with 593 patients with a 
recent diagnosis of T2DM, sleep debt resulted in long-
term metabolic disruption, which may promote the pro-
gression of the disease. This was concluded after exami-
nation of obesity status (by BMI), central adiposity (by 
waist circumference), and IR (fasting blood samples) and 
sleep debt assessed by 7-day sleep diaries (average week-
end sleep duration  minus average weekday sleep dura-
tion). The examination of cross-sectional and prospective 
associations between sleep debt and adiposity measures, 
as well as HOMA-IR in T2DM at baseline, 6 months, and 
12 months after lifestyle intervention, showed marked 
changes: for every 30 min of weekday sleep debt, the risk 
of obesity and IR at 12 months increased by 18 and 41%, 
respectively. At baseline, these people compared to those 
without weekday sleep debt, were 72% more likely to be-
come obese, while 6 months later, the sleep debt was sig-
nificantly associated with obesity and IR after adjustment 
(OR = 1.90 and 2.07, respectively). A further increase was 
observed at 12 months of sleep debt with OR of 2.10 and 
3.16, for obesity and IR, respectively  [99] .
 It has also been described that sleep quality rather than 
sleep duration plays an important role in IR in these new-
ly diagnosed T2DM patients. Because the average num-
ber of night awakenings was positively correlated with 
BMI and negatively associated with logged HOMA2-IR 
 [100] , BMI may mediate the relationship between indica-
tors of sleep quality and IR. These findings indicate the 
need for improving sleep quality to prevent the develop-
ment of obesity and IR as well as its progression to T2DM. 
The association between the genetic variants of the clock 
gene, obesity, and sleep duration has helped to identify at 
risk CLOCK genotypes, a fact that may help to identify 
individuals who are more susceptible to overeating and 
gaining weight when experiencing sleep deprivation 
 [101] .
 Chrononutrition 
 This term refers to a new field linking nutrition and 
circadian regulation. It refers not only to the food as a 
modulator of circadian clocks but also to the time at 
which those meals are eaten. As previously mentioned, 
feeding time sets the phase of peripheral circadian clocks. 
Time-restricted feeding for only a week impairs the phase 
of the clock and clock-controlled gene rhythmic expres-
sion in peripheral tissues, uncoupling them from the cen-
tral pacemaker in the SCN  [102] . The liver can easily 
adapt to a new feeding time in about 3 days, and the bal-
ance between food intake and starvation periods sets the 
phase. Eating at night shortens the starvation period 
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causing phase alterations in peripheral clocks  [103, 104] . 
A well-balanced diet may induce a rapid phase shift in the 
liver clock: a combination of carbohydrate and protein is 
effective, while protein, sugar, or oil is not  [103, 105] . An 
intraperitoneal injection of glucose combined with ami-
no acids can reset the liver clock by modulating the ex-
pression levels of clock core genes  [106] . Therefore, nu-
trients containing glucose and amino acids can induce 
rapid changes in the expression of clock genes, especial-
ly Per2 and Rev-erbα. Other common diet components 
such as caffeine  [107] , salt  [108] , and resveratrol  [109] , 
may alter circadian rhythms at the molecular level. Fi-
nally, the effects of a high-fat diet on the circadian system 
are very important for the general population, and also 
researchers, because globalization has spread out western 
or cafeteria diet worldwide. In fact, feeding mice with a 
high-fat diet disrupts feeding behavior and molecular cir-
cadian rhythms in the liver and adipose tissue, indicating 
that this diet also affects the central clock  [110–113] . 
However, feeding mice with HFD in a time-restricted 
fashion prevents obesity even without reducing caloric 
content  [69, 114] . This may indicate a restoring effect 
over phase amplitude of clocks. Additionally, mice gained 
more weight when fed with a normal or a high-fat diet 
during resting time (day), than during activity period 
(night). Similar results were obtained feeding rats with a 
butter based high-fat diet during the light phase  [115] , 
resembling the night eating syndrome in humans. Fur-
ther, several human studies have demonstrated that to 
prevent obesity and its undesirable consequences, it is ad-
visable to make bigger breakfasts and smaller dinners and 
also early mealtimes in general  [116] .
 Obesity Prevention and Treatment 
 Traditional Approach 
 Because obesity represents a heavy burden for the 
health budget, the community and, the general popula-
tion, the big challenge is to increase awareness, resources, 
and tools to identify pathogenic factors and design com-
prehensive and individualized treatment strategies  [117, 
118] . Consequently, current recommendations for obe-
sity management provide a general framework for appro-
priate, safe, and effective implementation of available 
treatment options  [119–121] ( Fig. 6 ). Across the recom-
mendations, comprehensive  lifestyle management, in-
cluding meal planning, exercise, and behavioral interven-
tion, is the cornerstone of all weight loss treatment ap-
propriate for all obese people. The success of this approach 
depends on 3 key components: reduced calorie intake, 
increased physical activity, and behavioral intervention. 
However, despite their best attempts, many people can-
not achieve successful long-term weight loss, even with 
extremely effective lifestyle intervention programs such 
as those used in the DPP and Look AHEAD trials  [122] . 
Pharmacotherapy is an appropriate option for people 
with BMI  ≥ 27 and complications or with BMI  ≥ 30, a rec-
ommendation consistent with label indications for ap-
proved agents  [123] . Regardless, drug therapy and more 
intensive interventions may be associated with lifestyle 
management. In general, any pharmacotherapy approved 
for long-term obesity management produced an average 
weight loss of 5–15% over 1 year when associated with 
intensive, comprehensive lifestyle intervention. Their 
use, however, has been associated with some adverse ef-
fects which have added specific warnings and precautions 
regarding their safe and effective use  [117, 123] . There-
fore, these therapies might be reserved for people at great-
er health risk due to obesity-associated complications and 
for those who failed to achieve weight loss despite tight 
adherence to diet and physical activity. Although a com-
prehensive discussion on bariatric surgery is beyond the 
scope of our review, we need to mention that it might be-
come an appropriate treatment option for some patients. 
Commonly used bariatric procedures include gastric 
banding, Roux-en-Y gastric bypass, and sleeve gastrec-
tomy  [124–128] . On average, weight loss with bariatric 
surgery is greater than with nonsurgical interventions, 
around 15–35% depending on the procedure  [120, 129–
132] . Although bariatric surgery may result in greater 
weight loss than other obesity interventions, it is an inva-
sive procedure that requires important long-term com-
mitment and follow-up by patients and health-care teams. 
Consequently, current treatment recommendations re-
serve bariatric surgery for people with BMI  ≥ 40 or  ≥ 35 
with obesity-associated complications  [120, 126–128, 
133–135] . Those who are interested in further updating 
their knowledge on current alternatives for obesity treat-
ment will find a recent review to be a great help  [121, 136] .
 A Chronobiological Approach to Obesity Treatment 
 As mentioned before, environmental factors or stress-
ors of the so-called contemporary “24/7” societies have 
pronounced effects on metabolism producing circadian 
clock disruption  [137–139] . Furthermore, people whose 
work involves irregular time schedules and forced expo-
sure to bright LAN (night/shift workers) show significant 
disruptions in sleep architecture, and increased preva-
lence of obesity. These lines of evidence indicate that the 
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system fails to adjust properly to environmental and/or 
stressor changes disrupting overall metabolic homeosta-
sis. In time, this disruption could contribute to the in-
creasing worldwide prevalence of obesity/T2DM. Thus, 
and from the point of view of public health, it might be 
important to implement active awareness campaigns on 
the importance of appropriate timing for food intake, 
daytime activity, exposure to sunlight and proper sleep. 
In this context, melatonin is an interesting chronothera-
peutic option ( Fig. 6 ) which can reset the phase and am-
plitude of circadian rhythms  [140–142] . Animal models 
of obesity showed that melatonin also possesses cytopro-
tective properties which may prevent undesirable effects 
 [143, 144] such as inflammation process and others  [96, 
145] . On the other hand, several controlled trials have 
shown that melatonin administration is useful for treat-
ing metabolic and cardiovascular comorbidities  [146–
150] . As already mentioned, at an early stage, nonphar-
macological approaches are highly recommended, while 
drug treatment may be used in patients refractory to those 
approaches. Melatonin has limited toxicity effects and a 
stronger safety profile than many other pharmaceutical 
agents  [151] . In fact, very high melatonin doses (300 mg/
day) were administered safely and well tolerated for up to 
2 years in patients with lateral amyotrophic sclerosis 
 [152] . Consequently, melatonin administration in com-
bination with strategically timely administration of light 
therapy and appropriate food intake appears to be justi-
fied for normalizing melatonin amplitude and synchro-
nizing endogenous circadian rhythms in obesity. Its ad-
ministration time is critical though: by strengthening of 
circadian clock function with bright light in the morning 
and melatonin before bed time, plus tight control of glu-
cose/lipid homeostasis with proper timing of food intake 
(peripheral clock entraining); this combined regime 
would provide an ideal treatment for restoration of im-
Meal plan
Exercise
Behavior
Obese
Severely/morbidly
obese 
Overweight
Pharmacotherapy Bariatricsurgery
Chronotherapy
Bright light in
the morning 
Melatonin
before bed time
Proper timing
of food intake 
Adequate
sleep
BMI >27 with
complications 
BMI >30 
BMI >30 with
severe
complications 
BMI >35 with
complications 
BMI >40  
No contraindications
No side effects
Phenotypes Available treatments
Intensive
lifestyle
intervention
 Fig. 6. Algorithm for available interventions for different obese 
phenotypes.  Traditional approaches to lose weight and its pre-
scription sequence (including bariatric surgery) are represented in 
the first 3 columns of the figure. They also include specific indica-
tions. On the other hand, chronotherapeutic strategy (last column) 
and its components offer a new approach with potential great suc-
cess rate and few side effects. BMI, body mass index. 
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paired circadian rhythms, representing a cutting-edge 
nonpharmaceutical chronotherapeutic strategy for the 
treatment of obese patients.
 Conclusions and Remarks 
 A neuroendocrine, metabolic, and circadian view of 
obesity can help to understand the multiple and complex 
mechanisms involved in its development and mainte-
nance, as well as to provide new effective approaches for 
its control and treatment. In this regard, chronotherapy 
may be a promising approach. Although it is still difficult 
to precisely identify the initial impaired mechanism that 
triggers the development of the obese phenotype, it is 
clear that once established, it greatly contributes to its 
perpetuation. Until we can identify this mechanism, the 
awareness of the population regarding the importance of 
appropriate timing for food intake, daytime activity, ex-
posure to sunlight, and proper sleep time period repre-
sents an effective obesity prevention strategy.
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